309 related articles for article (PubMed ID: 16242075)
1. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.
Rao RD; Mladek AC; Lamont JD; Goble JM; Erlichman C; James CD; Sarkaria JN
Neoplasia; 2005 Oct; 7(10):921-9. PubMed ID: 16242075
[TBL] [Abstract][Full Text] [Related]
2. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins.
Wang X; Beugnet A; Murakami M; Yamanaka S; Proud CG
Mol Cell Biol; 2005 Apr; 25(7):2558-72. PubMed ID: 15767663
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
4. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E.
Fingar DC; Salama S; Tsou C; Harlow E; Blenis J
Genes Dev; 2002 Jun; 16(12):1472-87. PubMed ID: 12080086
[TBL] [Abstract][Full Text] [Related]
5. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
6. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
7. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
8. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
9. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
10. Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells.
Puli S; Jain A; Lai JC; Bhushan A
Neurochem Res; 2010 Jul; 35(7):986-93. PubMed ID: 20177775
[TBL] [Abstract][Full Text] [Related]
11. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells.
Fuchs BC; Finger RE; Onan MC; Bode BP
Am J Physiol Cell Physiol; 2007 Jul; 293(1):C55-63. PubMed ID: 17329400
[TBL] [Abstract][Full Text] [Related]
12. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
13. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
Bishop JD; Nien WL; Dauphinee SM; Too CK
J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation dynamics of eukaryotic initiation factor 4E binding protein 1 (4E-BP1) is discordant with its potential to interact with eukaryotic initiation factor 4E (eIF4E).
Showkat M; Beigh MA; Bhat BB; Batool A; Andrabi KI
Cell Signal; 2014 Oct; 26(10):2117-21. PubMed ID: 24975846
[TBL] [Abstract][Full Text] [Related]
15. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
17. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin.
Takano A; Usui I; Haruta T; Kawahara J; Uno T; Iwata M; Kobayashi M
Mol Cell Biol; 2001 Aug; 21(15):5050-62. PubMed ID: 11438661
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1.
El-Chaâr D; Gagnon A; Sorisky A
Int J Obes Relat Metab Disord; 2004 Feb; 28(2):191-8. PubMed ID: 14970836
[TBL] [Abstract][Full Text] [Related]
19. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
[TBL] [Abstract][Full Text] [Related]
20. Studies on the mechanism of resistance to rapamycin in human cancer cells.
Hosoi H; Dilling MB; Liu LN; Danks MK; Shikata T; Sekulic A; Abraham RT; Lawrence JC; Houghton PJ
Mol Pharmacol; 1998 Nov; 54(5):815-24. PubMed ID: 9804616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
